Hepatic Neuroendocrine Metastases: Chemo- or Bland Embolization?
Aggressive management of hepatic neuroendocrine (NE) metastases improves symptoms and prolongs survival. Because of the rarity of these tumors, however, the best method for hepatic artery embolization has not been established. We hypothesized that in patients with hepatic NE metastases, hepatic artery chemoembolization (HACE) would result in better symptom improvement and survival compared to bland embolization (HAE).
Retrospective review identified all patients with NE hepatic metastases managed by HACE or HAE at three institutions from January 1996 through December 2007.
We identified 100 patients managed by HACE (n = 49) or HAE (n = 51) that were similar with respect to age, gender, and primary tumor type. The percentage of patients experiencing morbidity, 30-day mortality, and symptom improvement were similar between the two groups (HACE vs. HAE: 2.4% vs. 6.6%; 0.8% vs. 1.8%; and 88% vs. 83%, respectively.) No differences in the median overall survival were observed between HACE and HAE from the time of the first embolization procedure (25.5 vs. 25.7 months, p = 0.79). Multivariate analysis revealed that resection of the primary tumor predicted survival (73.8 vs. 19.4 months, p < 0.04).
These data suggest that morbidity, mortality, symptom improvement, and overall survival are similar in patients with hepatic neuroendocrine metastases managed by chemo- or bland hepatic artery embolization.
KeywordsChemoembolization Embolization Hepatic artery Metastasis Neuroendocrine tumor Liver
This work was supported by the American College of Surgeons Resident Research Scholarship and National Institutes of Health Grant T32 CA009614 Physician Scientist Training in Cancer Medicine.
- 11.Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madhoff DC et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rate and survival. Cancer 2005;104:1590–1602. doi: 10.1002/cncr.21389.PubMedCrossRefGoogle Scholar
- 15.Stöckman F, Von Romatowski HJ, Reimold WV, Schuster R, Cruetzfeldt W. Hepatic artery embolization for the treatment of endocrine gastrointestinal tumors with liver metastases. Z Gastroenterol 1984;22:652–660.Google Scholar
- 17.Eriksson BK, Larsson EG, Skogseid BM, Löfberg Am, Lörelius LE, Oberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998;83:2293–2301. doi: 10.1002/(SICI)1097-0142(19981201)83:11<2293::AID-CNCR8>3.0.CO;2-E.PubMedCrossRefGoogle Scholar
- 39.Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L et al. Are capecitabine and oxaliplatin (XELOX) suitable treatment for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007;59:637–642. doi: 10.1007/s00280-006-0306-6.PubMedCrossRefGoogle Scholar